What Does LVEF 40-49% Mean?
An LVEF of 40-49% indicates heart failure with mildly reduced ejection fraction (HFmrEF), representing a distinct category of heart failure where the heart's pumping function is below normal but not severely impaired. 1
Understanding the Classification
According to the 2022 AHA/ACC/HFSA guidelines, heart failure is classified by LVEF into four categories 1:
- HFrEF (reduced EF): LVEF ≤40%
- HFmrEF (mildly reduced EF): LVEF 41-49%
- HFpEF (preserved EF): LVEF ≥50%
- HFimpEF (improved EF): Previous LVEF ≤40% that improved to >40%
Your LVEF of 40-49% places you in the HFmrEF category, which sits between reduced and preserved function.
Important Clarification: EKG vs. Echocardiogram
A critical caveat: LVEF cannot be measured from an EKG (electrocardiogram). LVEF is measured by:
- Echocardiography (ultrasound of the heart) - most common
- Cardiac MRI
- Nuclear imaging
- Cardiac catheterization
An EKG only shows electrical activity, not pumping function. You likely had an echocardiogram, not just an EKG.
What This Means Clinically
Dynamic Nature
HFmrEF is typically a transitional state 1:
- Patients may be improving from HFrEF (LVEF <40%)
- Or deteriorating toward HFrEF
- One measurement at one time point is insufficient - trajectory matters
Prognosis
The evidence on outcomes is nuanced:
- In coronary artery disease patients, LVEF 40-49% carries intermediate risk between preserved and reduced EF, with increased mortality and cardiac events compared to LVEF ≥50% 2
- Trajectory is critical: Patients whose LVEF worsens from 40-49% to <40% have significantly worse outcomes (7-fold increased mortality risk) compared to those who improve to ≥50% 3
- In a global heart failure study, LVEF 40-49% actually showed better outcomes than LVEF ≥50% (HR 0.88), though this varied by underlying cause 4
Diagnostic Requirements
HFmrEF diagnosis requires more than just LVEF 41-49% 1:
You must also have evidence of:
- Elevated natriuretic peptides (BNP or NT-proBNP), OR
- Echocardiographic evidence of elevated filling pressures (E/e' ≥15), OR
- Structural heart disease: left atrial enlargement or increased LV mass
Treatment Implications
Patients with HFmrEF should be treated similarly to HFrEF, especially if they previously had lower LVEF that improved 1. This includes:
- ACE inhibitors/ARBs or ARNI (sacubitril/valsartan)
- Beta-blockers
- Mineralocorticoid receptor antagonists (spironolactone/eplerenone)
- SGLT2 inhibitors
If your LVEF improved from <40% to 40-49%, do NOT stop heart failure medications - withdrawal can cause LVEF to drop again 1.
What You Need to Do
- Confirm the actual test performed - likely echocardiogram, not EKG
- Determine your LVEF trajectory - was it previously lower, higher, or is this the first measurement?
- Identify the underlying cause - ischemic heart disease, hypertension, valve disease, etc.
- Check for additional diagnostic criteria - natriuretic peptides, structural changes
- Plan follow-up echocardiography - typically at 6-12 months to assess trajectory 3, 5
The 6-month follow-up LVEF is particularly valuable prognostically - improvement >10% from baseline predicts better outcomes, while worsening predicts significantly worse outcomes 5.